Clinical pharmacology of anti-Alzheimer drugs (Q35688610)

9 August 2017

1 reference

title

Clinical pharmacology of anti-Alzheimer drugs (English)

1 reference

9 August 2017

0 references

3

Carlo Caltagirone

1 reference

9 August 2017

Carla Pettenati

1

1 reference

9 August 2017

Roberta Annicchiarico

series ordinal

2

1 reference

9 August 2017

publication date

1 December 2003

1 reference

Fundamental and Clinical Pharmacology

9 August 2017

published in

1 reference

9 August 2017

volume

17

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

659-672

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Cholinesterase inhibitors: A new class of psychotropic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Cholinergic deficits contribute to behavioral disturbance in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Effects of NMDA Modulation in Scopolamine Dementiaa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Risk of Alzheimer's disease and duration of NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Randomized pilot study of nimesulide treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

The relation between antioxidants and memory performance in the old and very old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Estrogen replacement therapy and memory in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

The role of estrogen in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Postmenopausal estrogen and prevention bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Prior to use of estrogen replacement therapy, are users healthier than nonusers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1472-8206.2003.00204.X

10.1046/J.1472-8206.2003.00204.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference